Alteogen, ALT-B4European substance patent approval sends shares 15% higher, Labgenomics 13% higher
Alteogen said 6month 9day that approval had been granted for the European substance patent registration of ALT-B4, sending its share price 15% higher. On the same day, Labgenomics' share price rose 13% on news of an investment by Stick Investment, while Japanese government bond yields and South Korean Treasury bond yields fell across the board in the bond market.
Get free 알테오젠 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Alteogen announced that 6month 9day a decision had been made to approve the registration of ALT-B4's European substance patent. The company explained that the patent strengthens the global exclusive rights to its SC platform. On the news, Alteogen's share price surged 15% that day.
ALT-B4is introduced as a substance related to Alteogen's SC platform. The company said the substance is related to the development of long-acting biopharmaceuticals. Registration of the European substance patent strengthens rights protection in Europe.
On the same day, Labgenomics' share price rose 13% in response to news of an investment by Stick Investment. The news was immediately reflected in trading. Whether the company has disclosed specific investment terms must be confirmed through individual disclosures.
In the bond market, Japanese government bond yields fell across the board on news that a review was under way to suspend reductions in bond purchases. Domestic government bond yields also fell across the board that day. Domestic government bond 3-year yields stood at an annual 3.856%.
This series of news items triggered simultaneous, widespread volatility in individual issues and the bond market. Investors need to check the company's original disclosure and the schedule for additional announcements. Further market disclosures can be found in each company's future business and financial schedule.